Record profit masks an earnings quality gap
IOB's ₹1,659.2 Cr net profit jumped 49.3% year-on-year. But dig into the delivery: 81% of that ₹1,353 Cr total came from PSLC commission and loan recovery—non-recurring items. The call reveals an honest operational story: solid momentum offset by sustainability risk.
₹1,659.2 Cr
+49.3% YoY
₹1,353 Cr
81% of headline profit
~₹266 Cr
ex non-recurring items
On the surface, IOB's first quarter looks like a blowout. Net profit at an all-time high of ₹1,659.2 Cr, up nearly 50% year-on-year, delivered on credit growth 22.75% and NIM holding steady at 3.37%. Asset quality best-in-cycle. Management delivered on guidance. Yet the market's verdict—day 1 pop of 0.71% faded to a 3.37% drop by day 3—hints that the real story is more muted. The tension between the headline and what's sustainable is the quarter.
Where the ₹1,659 Cr came from
Net interest income grew 34.3% year-on-year, a genuinely strong operational signal. But that income line is draped in non-recurring items. PSLC commission—the regulatory pass-through that sells priority-sector loan certificates to other banks—delivered ₹863 Cr this quarter. Recovery from technically written-off loans: ₹490 Cr. Together, ₹1,353 Cr. That is 81% of the reported ₹1,659.2 Cr profit. Absent those two lines, operating net profit sits closer to ₹266 Cr. Management, when pushed by analyst Ashok Ajmera on the call, defended these items as 'routine, every quarter, integral part of non-interest income, will continue going forward.' The detail matters: the call provided no quantification of PSLC or recovery as a percentage of full-year profit, and no decomposition of how much is truly recurring versus how much rides on the stock of written-off accounts and regulatory PSLC flows.
These are routine, every quarter. NII grew 34.3%, that's the real driver. PSLC and recovery are integral non-interest income and will continue going forward.
All-time high net profit ₹1,659 Cr, 49.3% YoY growth
Delivered exactly ₹1,659.2 Cr, growth confirmed. But 81% (₹1,353 Cr) from PSLC ₹863 Cr + recovery ₹490 Cr.
Supported but qualified
NIM 3.37% global, 3.48% domestic within guidance range
Delivered 3.37% global, 3.48% domestic. Slight beat on 3.3-3.35% guidance, within management confidence.
Supported
Credit growth 22.75% YoY; 13-14% guidance minimum
Delivered ₹3.22 L Cr advances vs ₹2.62 L Cr prior year. Well above conservative baseline; consistent with historical 20%+ average.
Supported
Asset quality best-in-cycle: GNPA 1.33%, slippage 0.06%
Verified: GNPA down 64 bps YoY from 1.97%. Net NPA 0.18%, down 14 bps. Slippage at historic low.
Supported
PSLC and recovery are routine and will continue at current levels
No precedent data, no quantification, no sustainability mechanism disclosed. Management defensive when pressed.
Overstated
What changed on this call
Three strategic shifts emerged. First, credit growth came in at 22.75% year-on-year—well above the 13-14% minimum guidance. Management noted this is the floor, not the ceiling, consistent with the last three years' 20%+ average. Second, IOB took a discipline decision: exited a ₹10,000 Cr corporate account in April that was pricing below 7%, below the 4.7% cost of deposits. The move temporarily dented the corporate loan book (down 10% quarter-on-quarter) but reaffirmed a 'no loss-making business' philosophy; management expects the ₹14,000 Cr pipeline to offset this by year-end, targeting 12-13% FY corporate growth. Third, two international moves: IFSCA licensed the bank for a GIFT City branch 3-4 months ago (operationalizing in ~2 months), with an early-stage target of $500 million book by FY-end. And FCNR deposit mobilization is doubling: ₹4.5 lakh NRI customers, $300 million current target to $600-650 million by September (end of regulatory dispensation). These are not mega-scale but signal a strategic pivot toward retail international expansion and pricing discipline over pure volume.
How the street is positioned
The market's reaction is instructive. The day-1 pop of +0.71% faded sharply: by day 3, the stock had given back the gain and more, down 3.37% from day 1 close. Today at ₹33.88, the stock sits 18.95% below its all-time high of ₹41.8, and below its 20-day, 50-day, and 200-day simple moving averages—a bearish technical picture. The RSI sits at 47.2 (neutral-to-weak). Ownership is ultra-concentrated: Government holds 92.44%, steady quarter-over-quarter. FII have crept to 0.43% (from 0.35% prior Q), and DII hold 4.28%, flat. The volume trend is increasing, but the flow context suggests neither strong conviction buying nor panic selling—instead, a market that bought the headline and sold the detail. That divergence is worth paying attention to.
NII growth 34.3% YoY—genuine core momentum
Credit growth 22.75% YoY, well ahead of 13-14% minimum guidance
Asset quality best-in-cycle: GNPA 1.33%, slippage 0.06%, lowest recent
NIM stable 3.37% global, 3.48% domestic; CASA discipline holding 41%
Corporate pricing discipline: exited ₹10K Cr sub-7% business for principle
81% of PAT (₹1,353 Cr) from PSLC and recovery—non-structural
Management defensive on PSLC/recovery sustainability; no detail provided
SMA 2 uptick ₹500 Cr quarter-on-quarter to ₹4,246 Cr; stress emerging
₹5,000 Cr equity raise Q3-Q4 will dilute the 92.44% government float
West Asia 'looming large'; macro headwind priced in
PSLC + recovery cyclicality and normalization
High₹1,353 Cr (81% of PAT) from these items. If they halve, headline profit drops 40%+. Management's 'routine' claim lacks credibility; no mechanism disclosed for why they persist at current scale.
SMA 2 migration and asset quality inflection
MediumSMA 2 up ₹500 Cr quarter-on-quarter to ₹4,246 Cr. While slippage remains best-in-cycle (0.06%), this signals early-stage stress at portfolio edges. West Asia pressure could accelerate migration.
Rate environment and NIM compression
MediumNIM guidance 3.3-3.4% depends on stable/rising rates and CASA hold at 41%. If rate cuts accelerate or competition for deposits rises, compression risk is real despite management confidence.
₹5,000 Cr equity raise—shareholder dilution
MediumGovernment holds 92.44%; equity raise will dilute minority. Unless government participates pro-rata, EPS dilution to the public float is a given in Q3-Q4.
Corporate book recovery and pipeline traction
Low–MediumManagement exited ₹10K Cr and expects recovery via ₹14K Cr pipeline by year-end (12-13% growth). If pipeline stalls or delays, growth guidance miss.
1 · Q2 organic profit and PSLC/recovery levels
The real test comes when PSLC and recovery roll through a normal quarter. Without an ₹1.35K Cr cushion, what does the organic run-rate look like? Track: (a) PSLC commission as a % of quarterly profit, (b) recovery realization, (c) whether core NII momentum persists.
2 · Corporate loan book recovery and pricing discipline hold
Management claims ₹14K Cr pipeline will offset the ₹10K Cr exit and drive 12-13% FY corporate growth. Watch for: pipeline realization, pricing (yield on corporate), and whether 'no loss-making business' discipline sticks or unwinds if growth slows.
3 · Equity raise timing, method, and government participation
₹5,000 Cr raise approved for Q3-Q4. Will it be QIP, rights, or public offering? Will Government participate pro-rata to avoid EPS dilution to the public float? This determines valuation risk in the next two quarters.
IOB delivered a quarter of solid operational execution on credit, NIM, and asset quality. The bank showed discipline (exiting a loss-making account), strategic thinking (GIFT City, FCNR), and authentic management communication (directly addressing SMA 2, West Asia, PSLC sustainability). But the headline profit is a mirage: 81% of ₹1,659.2 Cr came from one-time and cyclical items. The stock's day-1 pop fading to a day-3 decline is the market reading that gap correctly.
Treat this as a steady execution quarter, not a step-change. The organic profit sits closer to ₹266 Cr (implied, ex PSLC and recovery). The number to track from here is that organic run-rate in Q2 and beyond. Until management quantifies PSLC and recovery sustainability with hard precedent or mechanism, assume they are cyclical. The bull case is real and defensible (NII momentum, asset quality, execution), but it trades at a discount to the headline for good reason. Watch Q2.
Informational and educational content only. Not investment advice.